BRPI0414721A - formulações estabilizadas de fosfatidilserina - Google Patents

formulações estabilizadas de fosfatidilserina

Info

Publication number
BRPI0414721A
BRPI0414721A BRPI0414721-9A BRPI0414721A BRPI0414721A BR PI0414721 A BRPI0414721 A BR PI0414721A BR PI0414721 A BRPI0414721 A BR PI0414721A BR PI0414721 A BRPI0414721 A BR PI0414721A
Authority
BR
Brazil
Prior art keywords
formulations
preparations
phosphatidylserine
activity
stable
Prior art date
Application number
BRPI0414721-9A
Other languages
English (en)
Inventor
Dorit Platt
Avidor Shulman
Gai Ben Dror
Yoni Twito
Rassan Zuabi
Neta Scheinman
Original Assignee
Enzymotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymotec Ltd filed Critical Enzymotec Ltd
Publication of BRPI0414721A publication Critical patent/BRPI0414721A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/103—Extraction or purification by physical or chemical treatment of natural phosphatides; Preparation of compositions containing phosphatides of unknown structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

"FORMULAçõES ESTABILIZADAS DE FOSFATIDILSERINA". A presente invenção refere-se a preparações de PS estáveis, em forma de pó, líquidas e em dispersão, bem como métodos de produção das mesmas. Mais importante, as preparações estáveis de PS particularmente não possuem atividade residual de fosfolipase D, e os métodos de eliminação dessa atividade são também descritos aqui. Finalmente, são também fornecidos usos destas preparações de PS em nutracêuticos ou como agentes ativos de composições farmacêuticas.
BRPI0414721-9A 2003-09-25 2004-09-26 formulações estabilizadas de fosfatidilserina BRPI0414721A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL15813903A IL158139A0 (en) 2003-09-25 2003-09-25 Stabilized formulations of phosphatidyl serine
PCT/IL2004/000895 WO2005027822A2 (en) 2003-09-25 2004-09-26 Stabilized formulations of phosphatidylserine

Publications (1)

Publication Number Publication Date
BRPI0414721A true BRPI0414721A (pt) 2006-11-21

Family

ID=34073789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414721-9A BRPI0414721A (pt) 2003-09-25 2004-09-26 formulações estabilizadas de fosfatidilserina

Country Status (11)

Country Link
US (1) US8324187B2 (pt)
EP (1) EP1663157B1 (pt)
JP (1) JP5077841B2 (pt)
KR (2) KR101226787B1 (pt)
CN (1) CN1897919A (pt)
AU (1) AU2004273700C1 (pt)
BR (1) BRPI0414721A (pt)
CA (1) CA2540170C (pt)
ES (1) ES2399049T3 (pt)
IL (2) IL158139A0 (pt)
WO (1) WO2005027822A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
EP2308324A1 (en) 2005-05-31 2011-04-13 Arla Foods amba Phosphatidylserine enriched milk fractions for the formulation of functional foods
NZ569235A (en) * 2005-12-15 2011-12-22 Nestec Sa Compositions and methods for preserving brain function using medium chain triglycerides
US8877239B2 (en) * 2010-08-12 2014-11-04 Nutritional Therapeutics, Inc. Lipid supplements for maintaining health and treatment of acute and chronic disorders
DE102007042557A1 (de) 2007-09-07 2009-03-19 Membramed Gmbh Neuartige Formulierung von Phospholipiden
JP5432563B2 (ja) * 2009-03-31 2014-03-05 株式会社ファンケル ホスファチジルセリン含有カプセル及びカプセル充填用ホスファチジルセリン組成物
CA2773523A1 (en) * 2009-09-11 2011-03-17 Nestec S.A. Compositions and methods for enhancing cognitive and related functions in animals
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
WO2012143860A1 (en) * 2011-04-18 2012-10-26 Jian Guan Ameliorating cognitive decline
CN102908336B (zh) * 2011-08-05 2015-10-28 深圳市华正实业有限公司 磷脂酰丝氨酸的稳定制剂、其制备方法、应用和应用产物
ITPD20120021A1 (it) 2012-01-26 2013-07-27 Fidia Farmaceutici "nuove composizioni farmaceutiche contenenti fosfatidilserina e curcumina".
ITMI20121784A1 (it) * 2012-10-22 2014-04-23 Velleja Res Srl Composizioni galattogeniche a base di fosfatidilserina
US9101580B2 (en) * 2012-12-18 2015-08-11 Matthew Bennett Compositions and methods for treating traumatic brain injury
EP2769725B1 (en) * 2013-02-22 2016-06-29 Lipogen Ltd. Compositions for use in alleviating symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder
US20170209471A1 (en) * 2014-07-25 2017-07-27 Enzymotec Ltd. Nutritional compositions containing phosphatidylserine powder
CN104327114A (zh) * 2014-11-06 2015-02-04 江南大学 一种磷脂酰丝氨酸的制备方法
WO2017125816A1 (en) * 2016-01-21 2017-07-27 Enzymotec Ltd. Methods using phosphatidylserine powder
CN106085984B (zh) * 2016-06-02 2019-07-19 天津科技大学 一种新型磷脂酶d及其制备磷脂酸、磷脂酰丝氨酸的方法
CN107125752B (zh) * 2017-06-14 2020-06-30 安徽省芬格欣生物药业有限公司 一种增进记忆功能的磷脂酰丝氨酸口服液及制备方法
CN107034248A (zh) * 2017-06-19 2017-08-11 成都新柯力化工科技有限公司 一种连续高效酶转化合成食品用磷脂酰丝氨酸的方法
CN107722051B (zh) * 2017-08-24 2020-08-14 南通励成生物工程有限公司 制备磷脂酰丝氨酸盐的方法
GB201821049D0 (en) * 2018-12-21 2019-02-06 Ge Healthcare As Ultrasound contrast agent and methods for use therof
US20220249455A1 (en) * 2019-07-15 2022-08-11 R.P. Scherer Technologies, Llc Enteric proton pump inhibitor softgel capsule
CN110938090A (zh) * 2019-12-24 2020-03-31 南通励成生物工程有限公司 一种磷脂酰丝氨酸的纯化方法
CN112314949A (zh) * 2020-11-04 2021-02-05 上海欧睿生物科技有限公司 一种磷脂酰丝氨酸液体配制方法
KR102754261B1 (ko) * 2022-05-12 2025-01-10 주식회사 한국인삼공사 붕해성이 개선된 포스파티딜세린 함유 연질캡슐
KR20260010331A (ko) * 2024-07-12 2026-01-20 주식회사 아스트로젠 L-세린의 리포좀 제형 및 이의 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3357918A (en) 1964-05-27 1967-12-12 Central Soya Co Fluidized lecithin composition and method
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5700668A (en) * 1995-12-08 1997-12-23 Italfarmaco Sud S.P.A. Process for the industrial preparation of phosphatidylserine
IL129086A0 (en) 1999-03-22 2000-02-17 Enzymotec Ltd Surfactant-lipase complex immobilized on insoluble matrix
DE69906345T2 (de) * 1998-10-30 2004-02-12 Merck Patent Gmbh Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
DE19917249C2 (de) 1999-02-26 2001-09-27 Meyer Lucas Gmbh & Co Verfahren zur Herstellung von Phosphatidylserin-Produkten
US6323060B1 (en) * 1999-05-05 2001-11-27 Dense-Pac Microsystems, Inc. Stackable flex circuit IC package and method of making same
JP4306899B2 (ja) 1999-10-26 2009-08-05 株式会社ヤクルト本社 ホスファチジルセリン含有油溶組成物の製造法
WO2001082902A1 (en) * 2000-04-28 2001-11-08 Zengen, Inc. Method and composition for rapid delivery of bioactive compounds to the systemic circulation via the nasal membrane
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP2001354680A (ja) 2000-06-08 2001-12-25 Nof Corp 高安定性酸性リン脂質および製造方法
IT1319679B1 (it) 2000-12-05 2003-10-23 Chemi Spa Processo di purificazione di fosfatidilserina.
JP4009066B2 (ja) 2001-02-15 2007-11-14 株式会社ヤクルト本社 ホスファチジルセリンの分画法
DE50200436D1 (de) * 2001-03-26 2004-06-17 Giventis Gmbh Nahrungsmittel zur steigerung der kognitiven leistungsfähigkeit
JP4599604B2 (ja) 2002-04-19 2010-12-15 カーギル テクスチュアライジング ソリューションズ ドイチュラント ゲゼルシャフト ミット ベシュレクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 生体活性のリン脂質含有成分を含有するマトリックス
CN1306736C (zh) 2003-06-13 2007-03-21 松下电器产业株式会社 用于射频光学传输的系统和方法
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
RU2480474C2 (ru) * 2005-04-28 2013-04-27 Энзимотек Лтд. Смеси полярных липидов, их получение и применение

Also Published As

Publication number Publication date
KR101226787B1 (ko) 2013-01-25
JP2007506733A (ja) 2007-03-22
WO2005027822A2 (en) 2005-03-31
CA2540170A1 (en) 2005-03-31
EP1663157B1 (en) 2012-11-28
US8324187B2 (en) 2012-12-04
AU2004273700C1 (en) 2010-03-11
IL158139A0 (en) 2004-09-27
KR20120039752A (ko) 2012-04-25
JP5077841B2 (ja) 2012-11-21
IL174420A (en) 2015-02-26
IL174420A0 (en) 2006-08-01
WO2005027822A3 (en) 2005-10-06
AU2004273700A1 (en) 2005-03-31
CN102160651A (zh) 2011-08-24
HK1092703A1 (en) 2007-02-16
CN1897919A (zh) 2007-01-17
ES2399049T3 (es) 2013-03-25
US20070160659A1 (en) 2007-07-12
KR20060123100A (ko) 2006-12-01
AU2004273700B2 (en) 2009-10-29
EP1663157A2 (en) 2006-06-07
CA2540170C (en) 2012-02-21
EP1663157A4 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
BRPI0414721A (pt) formulações estabilizadas de fosfatidilserina
DE60311567D1 (de) Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
MXPA05002814A (es) Formulacion para agentes lipofilicos.
DK1641483T3 (da) Fusionsproteiner
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2004043363A3 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
MY143795A (en) Tetrahydropyridoindole derivatives
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
BRPI0407181A (pt) Formulação farmacêutica
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer
PL1962815T3 (pl) Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
BRPI0412989A (pt) combinação farmacêutica útil para mobilização de célula-tronco
AU2003296692A1 (en) Lipidic protein-transfer systems and cosmetic/dermatological use thereof
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
WO2007077318A3 (fr) Utilisation d'un extrait peptidique de riz en tant qu'agent actif inducteur de la synthese des proteines sirt dans les cellules de la peau
BRPI0409790A (pt) 7-azaindóis e seu uso como terapêuticos
DE60225844D1 (de) Micelle-zusammensetzungen enthaltend pegylierten phospholipide und einen photosensibilisator
WO2007003771A3 (fr) Utilisation d'un extrait de levure en tant qu'agent actif inducteur de la synthese des proteines sirt dans les cellules de la peau

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.A61K 9/08, A61K 9/10, A61K 9/14, A61K 9/18, A61P 25/00

Ipc: A61K 9/08 (2011.01), A61K 9/10 (2011.01), A61K 9/1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.